Ipilimumab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/1 mL (vial)
Reference Brands: Yervoy® (EU & US)
Category:
Oncology Cancer Care
pilimumab (brand name Yervoy®) is a monoclonal antibody used in oncology to treat cancers like melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). It works by blocking the CTLA-4 receptor on T-cells, which enhances the immune system’s ability to attack cancer cells. It is available in intravenous (IV) form with a strength of 5 mg/1 mL.
Ipilimumab is available in Injection
and strengths such as 5 mg/1 mL (vial).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ipilimumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ipilimumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ipilimumab (brand name Yervoy®) is a monoclonal antibody used in oncology as an immune checkpoint inhibitor. By blocking the CTLA-4 receptor on T-cells, Ipilimumab enhances the body’s immune response, allowing T-cells to more effectively recognize and attack cancer cells. It is primarily used in the treatment of melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC), among other cancers.
Ipilimumab is often combined with nivolumab (Opdivo®) for improved efficacy, especially in metastatic melanoma and other advanced cancers. It is administered as an intravenous (IV) infusion, available in a 5 mg/1 mL vial.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing